|
Scientific Literature
Finding peer-reviewed articles published in respected medical journals and the results from other scientific studies related to hyperhidrosis can be frustrating and time consuming. That's why we've compiled a library of clinical data here. The articles, posters, and study data provided represents the best medical and scientific information to-date regarding the physiology, treatment, and effects of hyperhidrosis. New data and results will be posted as they become available. If you know of clinical information that should be included here, please let us know.
Gelbard, Christina M. MD, et al. “Primary pediatric hyperhidrosis: a review of current treatment options”. Pediatric Dermatology 25:6 (2008): 591-598.
Flanagan, Katherine H. MD, et al. “Botulinum toxin type A versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis”. Journal of Drugs in Dermatology 7:3 (2008): 221-227.
Smalls, Lola Kelly PhD, MBA, et al. “Clinical comparison of otc products labeled ‘prescription strength wetness protection’ to prescription antiperspirants”, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Smalls, Lola Kelly PhD, MBA, et. al. “Chromophore mapping of hemoglobin for the assessment of axillary irritation: comparison of otc and prescription antiperspirants”, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Solish, Nowell MD, FRCPC, et al. “A comprehensive approach
to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee”. Dermatol Surg 33 (2007): 908-923.
Bechara, Falk G. MD, et al. “Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A”. Dermatol Surg 33 (2007): 924-927.
NAD Examines Advertising for P&G's 'Secret Clinical Strength,' National Advertising Review Council, New York, NY, July 2007.
Ram, Ramin MD, et al. “Current and emerging therapeutic modalities for hyperhidrosis, part 2:
moderately invasive and invasive procedures”. Cosmetic Dermatology 79 (2007): 281-288.
Glaser, Dee Anna MD, et al. “Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years”, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Kessler, Edward, B.A., et al. “A demographical study of hyperhidrosis”, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, D.C.
Glaser, Dee Anna MD, et al. “4-Year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis”, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Thomas, Mike BS, MBA, et al. “Alternative topical treatment to an aluminum chloride antiperspirant that provides prescription strength efficacy with significantly less irritation”, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Aghaei, Shahin MD. “Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population”. The International Society of Dermatology 46 (2007): 212-214.
Lear, William BSC, MD, et al. “An epidemiological study of hyperhidrosis". Dermatol Surg 33 (2007): S69-S75.
Talarico-Filho, Sergio MD, et al. “A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis”. Dermatol Surg 33 (2007): S44-S50.
Kavanagh, Gina M. MD & Shams, Kave MD. “Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis”. Journal of the American Academy of Dermatology 55:5 (2006): S115-S117.
Kavanagh, G.M., et al. “Topical glycopyrrolate should not be overlooked in treatment of”. British Journal of Dermatology 155:2 (2006): 487.
Pariser, David MD, et al. “Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study”, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Thomas, Mike MBA, et al. “Panel discussions among hyperhidrosis patients to assess lifestyle limitations, treatment regimes, and compensating behaviors”, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Hamm, Henning, et al. “Primary focal hyperhidrosis: disease characteristics and functional impairment”. Dermatology 2006 212 (2006): 343-353.
Moya, J., et al. “Thoracic sympathicolysis for primary hyperhidrosis”. Surg Endosc 20 (2006): 598-602.
Glaser, Dee Anna MD, et al. “Efficacy and safety of repeated botulinum toxin type A treatment for primary axillary hyperhidrosis: 12-month interim analysis of a multicenter, open-label trial”, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Kowalski, Jonathan W. PharmD, MS, et al. “Cost-effectiveness and budget impact of botulinum toxin type A (BoNTA) treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents”, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Eisenach, John H. MD, et al. “Hyperhidrosis: evolving therapies for a well-established phenomenon”. Mayo Clinic Proceedings 80:5 (2005): 657-666.
Solish, Nowell MD, et al. “Prospective open-label study of botulinum toxin type A in patients with
axillary hyperhidrosis: effects on functional impairment and quality of life”. Dermatol Surg 31:4 (2005): 405-413.
Cliff, Sandeep H. FRCP & Reeken, Saskia. “Axillary hyperhidrosis and botox” responding to demands:
starting a nurse-led service”. Nurse2Nurse 5:1 (2005): 28-30.
Haider, Aamir & Solish, Nowell. “Focal hyperhidrosis: diagnosis and management”. CMAJ 172:1 (2005): 1-7.
Campanati, Anna MD, et al. “Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements”. Journal of the American Academy of Dermatology 51:3 (2004): 345-348.
Strutton, David R. PhD, MPH, et al. “US prevalence of hyperhidrosis and impact on individuals with
axillary hyperhidrosis: results from a national survey”. Journal of the American Academy of Dermatology 51:2 (2004): 241-248.
Hornberger, John MD, MS, et al. “Recognition, diagnosis, and treatment of primary focal hyperhidrosis”. Journal of the American Academy of Dermatology 51:2 (2004): 274-286.
Glaser, DA, et al. “Botulinum toxin type A improves occupational impairment associated with primary axillary hyperhidrosis and results in high levels of satisfaction with treatment”, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Carruthers, Alastair MD & Carruthers, Jean MD. “Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use”, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Kavanagh, G.M., et al. “Botox® delivery by iontophoresis”. British Journal of Dermatology 151 (2004): 1093-1095.
Ojimba, T.A. & Cameron, A.E.P. “Drawbacks of endoscopic thoracic sympathectomy”. British Journal of Surgery 91 (2004): 264-269.
Hund, Martina, et al. “Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis”. JDDG;2004· 2:343-349. (English, without graphs)
Hund, Martina, et al. “Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis”. JDDG;2004· 2:343-349. (German, with graphs)
Gossot, Dominique MD, et al. “Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis”. Ann Thoracic Surg 75 (2003): 1075-1079.
Naumann, M. MD, et al. “Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months”. Arch Dermatol 139 (2003): 731-736.
Kaufmann, Horacio, et al. “Primary hyperhidrosis”. Clin Auton Res 13 (2003): 96-98.
Tan, Stephen R. MD & Solish, Nowell MD FRCPC. “Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A”. Dermatol Surg 28:6 (2002): 495-499.
Davidson, Jonathan R.T., et al. “Hyperhidrosis in social anxiety disorder”. Progress in Neuro-Psychopharmacology &Biological Psychiatry 26 (2002): 1327-1331.
Naumann, M.K., et al. “Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial”. Brit J Dermatol 147 (2002): 1218-1226.
Naumann, M. & Lowe, N.J. “Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled trial”. BMJ 323 (2001): 596-599.
|
|
